As of January 18, 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. The UK was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020, and so far have administered 224.04 doses per 100. At the latest data, Belgium had carried out 253.89 doses of vaccines per 100 population. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of August 4, 2022, Russia had administered 127.3 doses per 100 people in the country.

The seven-day rate of cases across Europe shows an ongoing perspective of which countries are worst affected by the virus relative to their population. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

The data source for this dataset is the NI Vaccine Management System (VMS). VMS holds vaccination reports for COVID-19 and influenza vaccines which were either administered in NI or to NI residents. This dataset is an aggregated summary of COVID-19 vaccinations recorded in VMS. It is effectively a day-by-day count of living people vaccinated by dose, age band (on the day that the dataset was extracted from VMS) and LGD of residence. Aggregated summary data from VMS is published daily to the NI COVID-19 Vaccinations Dashboard. This dataset is updated weekly and allows NI vaccination coverage to be included in the GOV.UK Coronavirus (COVID-19) in the UK dashboard.

View daily updates and historical trends for UK Coronavirus Full Vaccination Rate. from United Kingdom. Source: Our World in Data. Track economic data wit…

Dataset description

Daily official UK Covid data. The data is available per country (England, Scotland, Wales and Northern Ireland) and for different regions in England. The different regions are split into two different files as part of the data is directly gathered by the NHS (National Health Service). The files that contain the word 'nhsregion' in their name, include data related to hospitals only, such as number of admissions or number of people in respirators. The files containing the word 'region' in their name, include the rest of the data, such as number of cases, number of vaccinated people or number of tests performed per day. The next paragraphs describe the columns for the different file types.

Region files

Files related to regions (word 'region' included in the file name) have the following columns: - "date": date in YYYY-MM-DD format - "area type": type of area covered in the file (region or nation) - "area name": name of area covered in the file (region or nation name) - "daily cases": new cases on a given date - "cum cases": cumulative cases - "new deaths 28days": new deaths within 28 days of a positive test - "cum deaths 28days": cumulative deaths within 28 days of a positive test - "new deaths_60days": new deaths within 60 days of a positive test - "cum deaths 60days": cumulative deaths within 60 days of a positive test - "new_first_episode": new first episodes by date - "cum_first_episode": cumulative first episodes by date - "new_reinfections": new reinfections by specimen data - "cum_reinfections": cumualtive reinfections by specimen data - "new_virus_test": new virus tests by date - "cum_virus_test": cumulative virus tests by date - "new_pcr_test": new PCR tests by date - "cum_pcr_test": cumulative PCR tests by date - "new_lfd_test": new LFD tests by date - "cum_lfd_test": cumulative LFD tests by date - "test_roll_pos_pct": percentage of unique case positivity by date rolling sum - "test_roll_people": unique people tested by date rolling sum - "new first dose": new people vaccinated with a first dose - "cum first dose": cumulative people vaccinated with a first dose - "new second dose": new people vaccinated with a first dose - "cum second dose": cumulative people vaccinated with a first dose - "new third dose": new people vaccinated with a booster or third dose - "cum third dose": cumulative people vaccinated with a booster or third dose

Country files

Files related to countries (England, Northern Ireland, Scotland and Wales) have the above columns and also: - "new admissions": new admissions, - "cum admissions": cumulative admissions, - "hospital cases": patients in hospitals, - "ventilator beds": COVID occupied mechanical ventilator beds - "trans_rate_min": minimum transmission rate (R) - "trans_rate_max": maximum transmission rate (R) - "trans_growth_min": transmission rate growth min - "trans_growth_max": transmission rate growth max

NHS Region files

Files related to nhsregion (word 'nhsregion' included in the file name) have the following columns: - "new admissions": new admissions, - "cum admissions": cumulative admissions, - "hospital cases": patients in hospitals, - "ventilator beds": COVID occupied mechanical ventilator beds - "trans_rate_min": minimum transmission rate (R) - "trans_rate_max": maximum transmission rate (R) - "trans_growth_min": transmission rate growth min - "trans_growth_max": transmission rate growth max

It's worth noting that the dataset hasn't been cleaned and it needs cleaning. Also, different files have different null columns. This isn't an error in the dataset but the way different countries and regions report the data.

This dataset is no longer updated, find vaccination data here From 24 March 2022, Public Health Scotland (PHS) began reporting the number of people who have received a fourth dose of Covid-19 vaccination. Vaccine uptake statistics among care home residents and those who are severely immunosuppressed will be reported initially. PHS will include further updates as the Spring/Summer vaccination programme rolls out. In addition, as part of our continuous review of reporting, PHS made some changes to vaccine uptake statistics. From 24 March 2022, the deceased and those who no longer live in Scotland are no longer be included in vaccine uptake statistics. Historic trend data have been updated to take into account this new methodology for all apart from the Daily Trends by JCVI Priority Group table (more details about the data in this table are below). Scotland level data for all vaccinations administered (i.e. including those who have since died or moved from Scotland) are still available in the Daily Trend of All Vaccinations Delivered in Scotland table. Also from 24 March 2022, Dose 3/Booster doses are termed "Dose 3". To allow new data to be fully processed and available at 14:00, the Daily COVID-19 in Scotland and COVID-19 Vaccination in Scotland datasets will be temporarily unavailable from 12:45 to 14:00. During this window, the datasets will not be visible and any queries made to these datasets will return a 404 - Not found error. At all other times the datasets will be available in full as usual. PHS reviewed the JCVI priority group uptake figures from 18 November 2021, specifically how we derive the numerator and the denominator. The rational for the change is to ensure we report on most up to date living population for each group. For this, the list of individuals in each cohort has been refreshed to be more current. We have also removed individuals who have since died to reflect the current living population. From the 24 March 2022 those who are no longer living in Scotland have also been removed from the numerator and denominator for JCVI priority group uptake figures. This means all the JCVI cohorts and populations have changed for both numerator and denominators on these two dates and care should be taken when interpreting trends. On 08 December 2020, a Coronavirus (COVID-19) vaccine developed by Pfizer BioNTech (Comirnaty) was first used in the UK as part of national immunisation programmes. The AstraZeneca (Spikevax) vaccine was also approved for use in the national programme, and rollout of this vaccine began on 04 January 2021. Moderna (Vaxzevria) vaccine was approved for use on 8 January 2021 and rollout of this vaccine began on 07 April 2021. These vaccines have met strict standards of safety, quality and effectiveness set out by the independent Medicines and Healthcare Products Regulatory Agency (MHRA). Those giving the vaccine to others were the first to receive the vaccination. In the first phase of the programme, NHS Scotland followed the independent advice received from the Joint Committee on Vaccination and Immunisation (JCVI) and prioritised delivery of the vaccine to those with the greatest clinical need, in line with the recommended order of prioritisation. For booster vaccinations a similar approach has been adopted. Definitions used in the vaccine uptake by JCVI priority group resource can be found in the JCVI Priority Group Definitions table. Individuals can appear in more than one JCVI priority group. This dataset provides information on daily number of COVID vaccinations in Scotland. Data on the total number of vaccinations in Scotland is presented by day administered and vaccine type, by age group, by sex, by non-age cohorts and by geographies (NHS Board and Local Authority). As the population in the cohorts can change with time, these will be refined when updated data are available. Additional data sources relating to this topic area are provided in the Links section of the Metadata below. Data visualisation and additional notes are available on the Public Health Scotland - Covid 19 Scotland dashboard.

As of June 13, 2023, there have been almost 768 million cases of coronavirus (COVID-19) worldwide. The disease has impacted almost every country and territory in the world, with the United States confirming around 16 percent of all global cases.

COVID-19: An unprecedented crisis Health systems around the world were initially overwhelmed by the number of coronavirus cases, and even the richest and most prepared countries struggled. In the most vulnerable countries, millions of people lacked access to critical life-saving supplies, such as test kits, face masks, and respirators. However, several vaccines have been approved for use, and more than 13 billion vaccine doses had already been administered worldwide as of March 2023.

The coronavirus in the United Kingdom Over 202 thousand people have died from COVID-19 in the UK, which is the highest number in Europe. The tireless work of the National Health Service (NHS) has been applauded, but the country’s response to the crisis has drawn criticism. The UK was slow to start widespread testing, and the launch of a COVID-19 contact tracing app was delayed by months. However, the UK’s rapid vaccine rollout has been a success story, and around 53.7 million people had received at least one vaccine dose as of July 13, 2022.

Foot-and-mouth disease outbreaks in non-endemic countries can lead to large economic costs and livestock losses but the use of vaccination has been contentious, partly due to uncertainty about emergency FMD vaccination. Value of information methods can be applied to disease outbreak problems such as FMD in order to investigate the performance improvement from resolving uncertainties. Here we calculate the expected value of resolving uncertainty about vaccine efficacy, time delay to immunity after vaccination and daily vaccination capacity for a hypothetical FMD outbreak in the UK. If it were possible to resolve all uncertainty prior to the introduction of control, we could expect savings of £55 million in outbreak cost, 221,900 livestock culled and 4.3 days of outbreak duration. All vaccination strategies were found to be preferable to a culling only strategy. However, the optimal vaccination radius was found to be highly dependent upon vaccination capacity for all management objectives. We calculate that by resolving the uncertainty surrounding vaccination capacity we would expect to return over 85% of the above savings, regardless of management objective. It may be possible to resolve uncertainty about daily vaccination capacity before an outbreak, and this would enable decision makers to select the optimal control action via careful contingency planning.

BackgroundTyphoid persists as a major cause of global morbidity. While several licensed vaccines to prevent typhoid are available, they are of only moderate efficacy and unsuitable for use in children less than two years of age. Development of new efficacious vaccines is complicated by the human host-restriction of Salmonella enterica serovar Typhi (S. Typhi) and lack of clear correlates of protection. In this study, we aimed to evaluate the protective efficacy of a single dose of the oral vaccine candidate, M01ZH09, in susceptible volunteers by direct typhoid challenge.Methods and FindingsWe performed a randomised, double-blind, placebo-controlled trial in healthy adult participants at a single centre in Oxford (UK). Participants were allocated to receive one dose of double-blinded M01ZH09 or placebo or 3-doses of open-label Ty21a. Twenty-eight days after vaccination, participants were challenged with 104CFU S. Typhi Quailes strain. The efficacy of M01ZH09 compared with placebo (primary outcome) was assessed as the percentage of participants reaching pre-defined endpoints constituting typhoid diagnosis (fever and/or bacteraemia) during the 14 days after challenge. Ninety-nine participants were randomised to receive M01ZH09 (n = 33), placebo (n = 33) or 3-doses of Ty21a (n = 33). After challenge, typhoid was diagnosed in 18/31 (58.1% [95% CI 39.1 to 75.5]) M01ZH09, 20/30 (66.7% [47.2 to 87.2]) placebo, and 13/30 (43.3% [25.5 to 62.6]) Ty21a vaccine recipients. Vaccine efficacy (VE) for one dose of M01ZH09 was 13% [95% CI -29 to 41] and 35% [-5 to 60] for 3-doses of Ty21a. Retrospective multivariable analyses demonstrated that pre-existing anti-Vi antibody significantly reduced susceptibility to infection after challenge; a 1 log increase in anti-Vi IgG resulting in a 71% decrease in the hazard ratio of typhoid diagnosis ([95% CI 30 to 88%], p = 0.006) during the 14 day challenge period. Limitations to the study included the requirement to limit the challenge period prior to treatment to 2 weeks, the intensity of the study procedures and the high challenge dose used resulting in a stringent model.ConclusionsDespite successfully demonstrating the use of a human challenge study to directly evaluate vaccine efficacy, a single-dose M01ZH09 failed to demonstrate significant protection after challenge with virulent Salmonella Typhi in this model. Anti-Vi antibody detected prior to vaccination played a major role in outcome after challenge.Trial registrationClinicalTrials.gov (NCT01405521) and EudraCT (number 2011-000381-35).

CVD-COVID-UK, co-ordinated by the British Heart Foundation (BHF) Data Science Centre (https://bhfdatasciencecentre.org/), is one of the NIHR-BHF Cardiovascular Partnership’s National Flagship Projects.

CVD-COVID-UK aims to understand the relationship between COVID-19 and cardiovascular diseases through analyses of de-identified, pseudonymised, linked, nationally collated health datasets across the four nations of the UK. The consortium has over 400 members across more than 50 institutions including data custodians, data scientists and clinicians, all of whom have signed up to an agreed set of principles with an inclusive, open and transparent ethos.

Approved researchers access data within secure trusted/secure research environments (TREs/SDEs) provided by NHS England (England), the National Safe Haven (Scotland), the Secure Anonymised Information Linkage (SAIL) Databank (Wales) and the Honest Broker Service (Northern Ireland). A dashboard of datasets available in each nation’s TRE can be found here: https://bhfdatasciencecentre.org/areas/cvd-covid-uk-covid-impact/

This dataset represents the linked datasets in SAIL Databank’s TRE for Wales and contains the following datasets: • Welsh Longitudinal GP Dataset - Welsh Primary Care (Daily COVID codes only) (GPCD) • Welsh Longitudinal General Practice Dataset (WLGP) - Welsh Primary Care • Critical Care Dataset (CCDS) • Emergency Department Dataset Daily (EDDD) • Emergency Department Dataset (EDDS) • Outpatient Database for Wales (OPDW) • Outpatient Referral (OPRD) • Patient Episode Dataset for Wales (PEDW) • COVID-19 Test Results (PATD) • COVID-19 Test Trace and Protect (CTTP) - Legacy • COVID-19 Shielded People List (CVSP) • SARS-CoV-2 viral sequencing data (COG-UK data)-Lineage/Variant Data-Wales (CVSD) • Covid Vaccination Dataset (CVVD) • Annual District Death Daily (ADDD) • Annual District Death Extract (ADDE) • COVID-19 Consolidated Deaths (CDDS) • Intensive Care National Audit and Research Centre (ICCD) - Legacy - COVID only • Intensive Care National Audit and Research Centre (ICNC) • Welsh Dispensing Dataset (WDDS) - Legacy • Annual District Birth Extract (ADBE) • Maternity Indicators Dataset (MIDS) • National Community Child Health Database (NCCHD) • Care Home Dataset (CARE) • Congenital Anomaly Register and Information Service (CARS) • Referral to Treatment Times (RTTD) • SAIL Dementia e-Cohort (SDEC) • Welsh Ambulance Services NHS Trust (WASD) • Welsh Demographic Service Dataset (WDSD) • Welsh Results Reports Service (WRRS) • ONS 2011 Census Wales (CENW)

Due to changes in the collection and availability of data on COVID-19 this page will no longer be updated. The webpage will no longer be available as of 11 May 2023. On-going, reliable sources of data for COVID-19 are available via the COVID-19 dashboard, Office for National Statistics, and the UKHSA This page provides a weekly summary of data on deaths related to COVID-19 published by NHS England and the Office for National Statistics. More frequent reporting on COVID-19 deaths is now available here, alongside data on cases, hospitalisations, and vaccinations. This update contains data on deaths related to COVID-19 from: NHS England COVID-19 Daily Deaths - last updated on 28 June 2022 with data up to and including 27 June 2022. ONS weekly deaths by Local Authority - last updated on 16 August 2022 with data up to and including 05 August 2022. Summary notes about each these sources are provided at the end of this document. Note on interpreting deaths data: statistics from the available sources differ in definition, timing and completeness. It is important to understand these differences when interpreting the data or comparing between sources. Weekly Key Points An additional 24 deaths in London hospitals of patients who had tested positive for COVID-19 and an additional 5 where COVID-19 was mentioned on the death certificate were announced in the week ending 27 June 2022. This compares with 40 and 3 for the previous week. A total of 306 deaths in hospitals of patients who had tested positive for COVID-19 and 27 where COVID-19 was mentioned on the death certificate were announced for England as whole. This compares with 301 and 26 for the previous week. The total number of COVID-19 deaths reported in London hospitals of patients who had tested positive for COVID-19 is now 19,102. The total number of deaths in London hospitals where COVID-19 was mentioned on the death certificate is now 1,590. This compares to figures of 119,237 and 8,197 for English hospitals as a whole. Due to the delay between death occurrence and reporting, the estimated number of deaths to this point will be revised upwards over coming days These figures do not include deaths that occurred outside of hospitals. Data from ONS has indicated that the majority (79%) of COVID-19 deaths in London have taken place in hospitals. Recently announced deaths in Hospitals 21 June 22 June 23 June 24 June 25 June 26 June 27 June London No positive test 0 0 1 4 0 0 0 London Positive test 3 7 2 10 0 0 2 Rest of England No positive test 2 6 4 4 0 0 6 Rest of England Positive test 47 49 41 58 6 0 81 16 May 23 May 30 May 06 June 13 June 20 June 27 June London No positive test 14 3 4 0 4 3 5 London Positive test 45 34 55 20 62 40 24 Rest of England No positive test 41 58 33 23 47 23 22 Rest of England Positive test 456 375 266 218 254 261 282 Deaths by date of occurrence 21 June 22 June 23 June 24 June 25 June 26 June 27 June London 20,683 20,686 20,690 20,691 20,692 20,692 20,692 Rest of England 106,604 106,635 106,679 106,697 106,713 106,733 106,742 Interpreting the data The data published by NHS England are incomplete due to: delays in the occurrence and subsequent reporting of deaths deaths occurring outside of hospitals not being included The total deaths reported up to a given point are therefore less than the actual number that have occurred by the same point. Delays in reporting NHS provide the following guidance regarding the delay between occurrence and reporting of deaths: Confirmation of COVID-19 diagnosis, death notification and reporting in central figures can take up to several days and the hospitals providing the data are under significant operational pressure. This means that the totals reported at 5pm on each day may not include all deaths that occurred on that day or on recent prior days. The data published by NHS England for reporting periods from April 1st onward includes both date of occurrence and date of reporting and so it is possible to illustrate the distribution of these reporting delays. This data shows that approximately 10% of COVID-19 deaths occurring in London hospitals are included in the reporting period ending on the same day, and that approximately two-thirds of deaths were reported by two days after the date of occurrence. Deaths outside of hospitals The data published by NHS England does not include deaths that occur outside of hospitals, i.e. those in homes, hospices, and care homes. ONS have published data for deaths by place of occurrence. This shows that, up to 05 August, 79% of deaths in London recorded as involving COVID-19 occurred in hospitals (this compares with 44% for all causes of death). This would suggest that the NHS England data may underestimate overall deaths from COVID-19 by around 20%. Comparison of data sources Note on data sources NHS England provides numbers of patients who have died in hospitals in England and had tested positive for COVID-19, and from 25 April, the number of patients where COVID-19 is mentioned on the death certificate and no positive COVID-19 test result was received. Figures are updated each day at 2pm with deaths reported up to 5pm the previous day. There is a delay between the occurrence of a death to it being captured in the daily reporting. The data can be presented both as reported deaths by day and death occurrences by day. Reported occurrences for recent days should be considered incomplete as likely to be revised upwards as more data becomes available. The location of a death reflects the location of the hospital in which it occurred. Source: NHS England COVID-19 Daily Deaths The Office for National Statistics publishes deaths for England and Wales by the week in which they were registered. Due to the delay between the occurrence of a death and its registration, many deaths that occur in a given week will appear in the data for a subsequent week. For 2018, ONS estimated that 74% of deaths were registered within seven days. Additional delays in registration can occur over public holidays, with significant changes in numbers being observable over Easter and Christmas. The location of a death reflects the usual residence of the deceased. There are some differences in total numbers reported for different geographical levels. The figures published at the local authority level have been used in this analysis. The data is updated each Tuesday at 9.30am with data for the week ending eleven days prior. For the 2020 series, ONS has included the number of deaths where coronavirus (COVID-19) was mentioned on the death certificate. This data includes deaths for all places of occurrence. The ONS started publishing deaths in care homes notified to the Care Quality Commission on 28th April for local authorities in England by date of notification. This data includes an additional week of data compared to the main ONS publication. Source: Deaths registered weekly in England and Wales, provisional, Death registrations and occurrences by local authority, Deaths in care homes notified to the Care Quality Commission, report

According to a survey conducted in the United Kingdom (UK) in April 2022, **** percent of all people aged between 35 and 49 years reported to be suffering from long COVID symptoms, the highest share across all age groups. Furthermore, around *** percent of the population aged 50 to 69 years were estimated to suffer from long COVID. Overall, around *** thousand people in the UK reported their ability to undertake daily activities and routines was affected a little by long COVID symptoms.

Present state of COVID-19 As of May 2022, over ** million COVID-19 cases had been reported in the UK. The largest surge of cases was noted over the winter period 2021/22. The incidence of cases in the county since the pandemic began stood at around ****** per 100,000 population. Cyprus had the highest incidence of COVID-19 cases among its population in Europe at ****** per 100,000 people, followed by a rate of ****** in Iceland. Over *** thousand COVID-19 deaths have been reported in the UK. The deadliest day on record was January 20, 2021, when ***** deaths were recorded. In the UK, a COVID-19 death is defined as a person who died within ** days of a positive test.

Preventing long COVID through vaccination According to the WHO, being fully vaccinated alongside a significant proportion of the population also vaccinated is the best way to avoid the spread of COVID-19 or serious symptoms associated with the virus. It is therefore regarded that receiving a vaccine course as well as subsequent booster vaccines limits the chance of developing long COVID symptoms. As of April 27, 2022, around **** million first doses, **** million second doses, and **** booster doses had been administered in the UK.

The aim of the publication is to inform users about activity and usage of GP appointments historically and how primary care is impacted by seasonal pressures, such as winter. The publication includes important information, however it does not show the totality of GP activity/workload. The data presented only contains information which was captured on the GP practice systems. This limits the activity reported on and does not represent all work happening within a primary care setting or assess the complexity of activity. No patient identifiable information has been collected or is included in this release. NHS Digital publishes this information to support winter preparedness and provide information about some activity within primary care. The publication covers historic appointments, marked as attended or did not attend, from national to sub ICB location coverage. The aim is to inform users, who range from a healthcare professional to an inquiring citizen, about appointments within primary care. The publication includes data from participating practices using EMIS, TPP, Eva Health formerly known as Microtest (up until February 2021), Informatica, Cegedim (previously Vision) and Babylon (GP at Hand) GP systems. NHS Digital produce this information monthly, containing information about the most recent month and previous months. Between December 2020 and present the data contained in this publication will no longer contain covid-19 vaccination activity collected from GP System Suppliers as part of the General Practice Appointments Data. These appointments have been removed using the methodology outlined in the supporting information. In order to gain a more complete picture of general practice activity we will publish covid-19 vaccination activity carried out by PCN’s or GP Practice’s from the NIMS (National Immunisation Management Service) vaccination dataset. This publication now includes statistics on the duration of appointments, SDS role and the recorded national category, service setting and context type of the appointment. Both HCP Type and SDS role are currently presented for comparison purposes, but moving forward the intention is to only publish SDS Role Groups and remove HCP Type. Further information can be found in the supporting guidance below.

Distribution of animals to treatment groups according to their physiological status at the day of vaccination (SD0).

Background. Dendritic cell (DC)-based neoantigen vaccination holds potential as a safe and effective adjuvant therapy for patients with early-stage, resectable NSCLC, a tumor type typically characterized by high mutational loads. DCs have the unique ability to elicit robust antitumoral T-cell responses, while neoantigens are ideal targets to elicit high-affinity T cell responses with exquisite tumor specificity. Here, we present the results of a phase I clinical trial in which a novel DC vaccine targeting neoantigens was evaluated in six patients with early stage, resected NSCLC. Methods. Tumor samples were subjected to a comprehensive neoantigen identification approach encompassing genomics, transcriptomics and immunopeptidomics. Using genomics and transcriptopmics data, tumor-specific antigens were identified by a bioinformatics approach. Additionally, immunopeptidomics was performed by immunoprecipitation of human MHC class I molecule followed by immunopeptides enrichment and LC-MS/MS analysis. Two immunopeptidomics screens were performed. In the first immunopeptidomics screen, patient-derived tumors were analyzed to uncover neoepitopes specific for the patient. In the second, screen, patient-derived EBV-immortilized B cell lines overexpressing the selected neoepitopes were analyzed to verify that the predicted neoepitopes can bind to the HLA haplotypes of the patients. For anti-tumor vaccination, patients underwent leukapheresis for the manufacturing of monocyte-derived DCs loaded with neoantigens (Neo-mDCs) according to a four-day protocol. Neo-mDCs were injected intravenously following an intrapatient dose escalation scheme. Primary endpoint of the trial was safety. Secondary endpoints were feasibility, immunogenicity, and relapse-free survival. Results. In the first immunopeptidomics screen, one neoepitopes derived was identified from the tumor of one patient. In the second immunopeptidomics screen, several predicted neoepitopes were confirmed to be presented on the HLA haplotypes of the patients by analyzing the patient-derived EBV-immortilized B cell lines. Additionally, the vaccine was demonstrated to be feasible and safe. T cell responses were observed in 5 of 6 vaccinated patients and were dominated by CD8+ T cells, which could be detected ex vivo at high frequencies >1.5 years after the last dose. Furthermore, single cell analysis indicated that the CD8+ T cell responsive population was polyclonal and exhibited the near entire spectrum of T cell differentiation states, including a naïve-like state associated with long lasting memory but excluding exhausted cell states. Three of six vaccinated patients experienced disease relapse. Conclusion. Neo-mDC vaccination is safe and feasible. Vaccination induces large populations of neoantigen-specific T-cell responses containing long lasting memory and effector cells in early-stage NSCLC patients, suggesting clinical potential.

The results of the monthly BVDV PCR analyses of bulk tank milk.

Anti-tick vaccines represent a promising alternative to chemical acaricides for the management of ticks on wildlife; however little progress has been made to produce an effective vaccine in hosts relevant to tick reproduction. Further, most of the antigens described are expressed during feeding in domesticated hosts and may not activate the immune system in wild hosts. We recently tested Amblyomma americanum salivary (SG) and midgut (MG) extracellular vesicles (EVs) as vaccine candidates in white-tailed deer (Odocoileus virginianus; WTD), which resulted in on-host female tick mortality. Herein, we describe our efforts to identify the antigenic proteins found within these vesicles. Within both SG- and MG-EVs, an enriched “core- cargo” was identified within both SG- and MG-EVs, including chaperones, small GTPases, and other proteins previously reported in small EVs was discovered. Label-free quantitative proteomics showed significant differences in protein cargo between MG and SG-EVs (333 proteins out of 516). Serum from three vaccinated WTD (pre-vaccinated and day 57 post vaccination) and one control WTD was used to immunoprecipitated antigenic proteins from SG- and MG-EV preparations. Proteomic analysis of immunoprecipitated proteins identified seven antigenic proteins in SG-EVs and one in MG-EVs that were statistically significantly different from the pre-vaccinated serum. Moreover, these proteins were unique to vaccinated animals (not precipitated by control serums). Additionally, two MG-EVs and 24 SG-EV proteins show antigenic potential. These proteins represent promising candidates for anti-tick vaccine design in WTD and other wildlife.

BackgroundPredicting the future UK COVID-19 epidemic provides a baseline of a vaccine-only mitigation policy from which to judge the effects of additional public health interventions. A previous 12-month prediction of the size of the epidemic to October 2022 underestimated its sequelae by a fifth. This analysis seeks to explain the reasons for the underestimation before offering new long-term predictions.MethodsA Dynamic Causal Model was used to identify changes in COVID-19 transmissibility and the public's behavioral response in the 12-months to October 2022. The model was then used to predict the future trends in infections, long-COVID, hospital admissions and deaths over 12-months to October 2023.FindingsThe model estimated that the secondary attack rate increased from 0.4 to 0.5, the latent period shortened from 2.7 to 2.6 and the incubation period shortened from 2.0 to 1.95 days between October 2021 and October 2022. During this time the model also estimated that antibody immunity waned from 177 to 160 days and T-cell immunity from 205 to 180 days. This increase in transmissibility was associated with a reduction in pathogenicity with the proportion of infections developing acute respiratory distress syndrome falling for 6–2% in the same twelve-month period. Despite the wave of infections, the public response was to increase the tendency to expose themselves to a high-risk environment (e.g., leaving home) each day from 33–58% in the same period.The predictions for October 2023 indicate a wave of infections three times larger this coming year than last year with significant health and economic consequences such as 120,000 additional COVID-19 related deaths, 800,000 additional hospital admissions and 3.5 million people suffering acute-post-COVID-19 syndrome lasting more than 12 weeks.InterpretationThe increase in transmissibility together with the public's response provide plausible explanations for why the model underestimated the 12-month predictions to October 2022. The 2023 projection could well-underestimate the predicted substantial next wave of COVID-19 infection. Vaccination alone will not control the epidemic. The UK COVID-19 epidemic is not over. The results call for investment in precautionary public health interventions.

Infoveillance, wastewater and national data.R - The R script used for the analyses and figures present in the manuscript. SWalesNormqPCRandGT.csv - File containing the data used for this manuscript, including the following columns: Study Week: The number of weeks into the period used for this study. WC Date: The date of the first day of each week used for this study. COVIDCount: The average normalised copy numbers of SARS-CoV-2 across sites and dates in South Wales for each week. covid symptoms: The relative prevalence of Google searches for the string “covid symptoms’. covid test: The relative prevalence of Google searches for the string “covid test’. covid vaccine: The relative prevalence of Google searches for the string “covid vaccine’. covid rules: The relative prevalence of Google searches for the string “covid rules’. covid lockdown: The relative prevalence of Google searches for the string “covid lockdown’. Cases: The number of COVID cases reported by Welsh Government for that week. Deaths: The number of COVID-related deaths reported by Welsh Government for that week. Vaccines: The number of COVID vaccines reported by Welsh Government for that week.